Related Experiment Video
Updated: Jan 10, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Olanzapine/Samidorphan (Lybalvi) in Palliative Care: A Case Report on Medication Reconciliation, Risk-Benefit
Sharely Fred-Torres1, Alcida Karz1, Lindsey Wright1
1NYU Grossman School of Medicine, NYU Langone Health, New York, New York, USA.
Abstract:
Patients with cancer have a high rate of comorbid psychiatric disorders. While the exact prevalence of comorbid bipolar I disorder and cancer is unknown, given the worse health outcomes associated with siloed specialist care, increased knowledge of the co-management of patients with cancer and bipolar I disorder is needed in palliative care. This case highlights a need for awareness regarding the specific combination of olanzapine and samidorphan (Lybalvi), approved in 2021 for the management of bipolar I disorder. Samidorphan, an opioid antagonist, mitigates the metabolic side effects of olanzapine. Notably, patients with comorbid bipolar I disorder and cancer often have both significant anorexia and pain, making samidorphan less desirable, as, in addition to mitigating metabolic side effects, it can limit the efficacy of analgesia from opioids. A recommendation of transitioning to olanzapine only is discussed.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Mania and Antimanic Drugs: Overview
Antidepressant Drugs: MAOIs and Other Agents
Treatment Resistant Cancers